ANCA-associated glomerulonephritis in the very elderly

Area of Science:

• Nephrology
• Immunology
• Geriatrics

Background:

• Antineutrophil cytoplasmic autoantibody (ANCA)-associated pauci-immune glomerulonephritis (GN) is common in elderly patients with acute kidney injury.
• Optimal treatment strategies for this demographic remain undefined due to uncertain risk-benefit ratios of immunosuppression.

Purpose of the Study:

• To evaluate the efficacy and safety of immunosuppression in patients over 80 years old with biopsy-proven pauci-immune GN.
• To identify factors influencing progression to end-stage renal disease (ESRD) in this elderly cohort.

Main Methods:

• Retrospective cohort study of 78 patients aged >80 years with biopsy-proven pauci-immune GN.
• Analysis of treatment with immunosuppression versus no immunosuppression.
• Assessment of outcomes including ESRD and mortality at 1 year and extended follow-up.

Main Results:

• Patients treated with immunosuppression had significantly lower rates of ESRD at 1 year (36% vs. 73%, P=0.03).
• Peak serum creatinine and immunosuppression use were key factors for ESRD progression.
• No significant difference in 1-year mortality was observed (46% vs. 64%, P=0.3).
• Extended follow-up showed immunosuppression was associated with reduced risk of death (HR 0.33) and death or ESRD (HR 0.16).

Conclusions:

• Immunosuppression appears beneficial in elderly patients (>80 years) with ANCA-associated pauci-immune GN, significantly reducing ESRD progression.
• While short-term mortality is not improved, long-term survival and combined outcomes are better with immunosuppression.
• Treatment decisions should consider the potential long-term benefits of immunosuppression in this vulnerable population.